Apellis Pharmaceuticals (APLS) Projected to Post Earnings on Thursday

Key Points

• Apellis Pharmaceuticals is set to release its Q3 2025 earnings report on October 30, 2025, with expectations of earnings at $0.73 per share and revenue of $364.58 million.
• After its last quarterly update, Apellis reported a loss of ($0.33) EPS but exceeded the consensus estimate by $0.11, though revenue decreased by 10.6% year-over-year.
• The stock has a current market capitalization of $3.55 billion, and analysts hold a consensus target price of $33.47, indicating an average "Hold" rating.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) will likely be posting its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect Apellis Pharmaceuticals to post earnings of $0.73 per share and revenue of $364.5790 million for the quarter. Individuals may visit the the company's upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, October 30, 2025 at 8:30 AM ET.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.11. Apellis Pharmaceuticals had a negative return on equity of 116.09% and a negative net margin of 30.24%.The company had revenue of $171.39 million during the quarter, compared to analyst estimates of $187.91 million. During the same quarter in the previous year, the firm earned ($0.30) earnings per share. Apellis Pharmaceuticals's revenue was down 10.6% on a year-over-year basis. On average, analysts expect Apellis Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Apellis Pharmaceuticals Stock Down 0.6%

Shares of NASDAQ APLS opened at $28.14 on Thursday. Apellis Pharmaceuticals has a 12 month low of $16.10 and a 12 month high of $35.72. The company has a current ratio of 3.77, a quick ratio of 3.16 and a debt-to-equity ratio of 2.90. The firm has a market capitalization of $3.55 billion, a price-to-earnings ratio of -15.46 and a beta of 0.69. The business has a 50-day moving average of $25.57 and a 200-day moving average of $21.31.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Royal Bank Of Canada boosted their price objective on Apellis Pharmaceuticals from $17.00 to $19.00 and gave the stock a "sector perform" rating in a report on Friday, August 1st. Wall Street Zen raised Apellis Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, August 2nd. Morgan Stanley upped their target price on Apellis Pharmaceuticals from $25.00 to $26.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 2nd. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Apellis Pharmaceuticals in a research note on Wednesday, October 8th. Finally, JPMorgan Chase & Co. upped their target price on Apellis Pharmaceuticals from $35.00 to $37.00 and gave the stock an "overweight" rating in a research note on Monday, August 4th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $33.47.

Insider Activity

In related news, Director A. Sinclair Dunlop sold 31,092 shares of the company's stock in a transaction that occurred on Friday, October 10th. The stock was sold at an average price of $23.72, for a total transaction of $737,502.24. Following the completion of the transaction, the director owned 3,837 shares in the company, valued at $91,013.64. This represents a 89.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, General Counsel David O. Watson sold 5,000 shares of the company's stock in a transaction that occurred on Thursday, October 16th. The shares were sold at an average price of $25.22, for a total value of $126,100.00. Following the transaction, the general counsel owned 113,730 shares of the company's stock, valued at approximately $2,868,270.60. This represents a 4.21% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 302,921 shares of company stock valued at $8,210,566. 6.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Apellis Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in APLS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Apellis Pharmaceuticals by 207.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,559 shares of the company's stock valued at $667,000 after acquiring an additional 19,944 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Apellis Pharmaceuticals by 26.6% during the first quarter. Goldman Sachs Group Inc. now owns 307,709 shares of the company's stock valued at $6,730,000 after acquiring an additional 64,742 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Apellis Pharmaceuticals by 4.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 222,634 shares of the company's stock valued at $4,869,000 after acquiring an additional 9,747 shares in the last quarter. Focus Partners Wealth raised its holdings in shares of Apellis Pharmaceuticals by 118.4% during the first quarter. Focus Partners Wealth now owns 21,883 shares of the company's stock valued at $479,000 after acquiring an additional 11,862 shares in the last quarter. Finally, Acadian Asset Management LLC raised its holdings in shares of Apellis Pharmaceuticals by 1,146.2% during the first quarter. Acadian Asset Management LLC now owns 23,976 shares of the company's stock valued at $522,000 after acquiring an additional 22,052 shares in the last quarter. Institutional investors own 96.29% of the company's stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.